Maarten van der Doelen

Impact of DNA damage repair defects on response to radium-223 therapy in mCRPC patients

Group DDR + N = 28 P

7 Both Abiraterone and Enzalutamide 93 26 (28.0) 20 (30.8) 6 (21.4) 0.357 Number of prior registered therapies, median (IQR) 93 2 (1-2) 2 (1-2) 2 (1-2) 0.927 Extent of bone metastases b , n (%) 89 Low volume 10 (11.2) 7 (11.1) 3 (11.5) 0.542

Metastatic prostate cancer at diagnosis 92 50 (54.3) 34 (53.1) 16 (57.1) 0.722 Prior registered systemic therapies, n (%) None 93 11 (11.8) 8 (12.3) 3 (10.7) 1.000 Taxane-based chemotherapy 93 52 (55.9) 36 (55.4) 16 (57.1) 0.876 Docetaxel chemotherapy a 92 50 (54.3) 34 (53.1) 16 (57.1) 0.722

Cabazitaxel chemotherapy 92 9 (9.8) 9 (10.9) 2 (7.1) 0.717 Abiraterone 93 50 (53.8) 34 (52.3) 16 (57.1) 0.668 Enzalutamide 93 48 (51.6) 35 (53.8) 13 (46.4) 0.511

Intermediate volume (6-20 bone metastases) 39 (43.8) 30 (47.6) 9 (34.6) High volume (>20 bone metastases) 38 (42.7) 25 (39.7) 13 (50.0) Superscan c 2 (2.2) 1 (1.6) 1 (3.8) Lymph node metastases, n (%) 92 21 (22.8) 15 (23.4) 6 (21.4) 0.833

Age, median (IQR), years 93 68 (62-74) 69 (62-75) 65 (61-71) 0.164 Initial tumor staging, n (%) 90

0.076 ISUP classification 2-3 16 (17.8) 14 (22.2) 2 (7.4)

ISUP classification 1 3 (3.3) 1 (1.6) 2 (7.4)

ISUP classification 4-5 71 (78.9) 48 (73.8) 23 (85.2)

Group DDR - N = 65

N = 93

Complete cohort

N

Table 1. Baseline patient demographics and clinical characteristics.

181